Mater Health Services (Mater Misericordiae Health Services Brisbane Limited) is facing a s.372 (Application to deal with other contravention disputes) lodged by a staffer (Graham).
October 6, 2017
Victorian aged care provider Lyndoch Living has announced the appointment of Fiona Moore as director of people and resilience.
October 6, 2017
A new alliance has been formed between Neuroscience Research Australia (NeuRA) and University of New South Wales (UNSW), with Professor Kaarin Anstey announced to lead a multi-disciplinary team addressing research on ageing and dementia.
October 6, 2017
Lutheran Church of Australia Queensland District is facing a s.394 (Application for unfair dismissal remedy) before Commissioner Simpson in his Brisbane chambers (Bos).
October 6, 2017
Regis Aged Care Pty Ltd is set to counter a s.394 (Application for unfair dismissal remedy) before Commissioner McKenna in Hearing Room 12-2 – level 12 in Sydney (Wang).
October 6, 2017
The Department of Human Services has a (s.739 – Application to deal with a dispute in relation to flexible working arrangements) set for hearing before Commissioner Williams in the Fair Work Commission Level 12, 111 St Georges Terrace Perth at 10am (Cooke).
October 6, 2017
KinCare, In-home Carers will defend a s.365 (Application to deal with contraventions involving dismissal) before Commissioner Cirkovic in Court 10 – level 5 in Melbourne at 3pm (Dennehy).
October 6, 2017
A man who died at Fiona Stanley Hospital (FSH) after having an adverse reaction to an anti-inflammatory drug would likely still be alive if results of his blood tests had been checked by doctors, the WA Coroner has found. Jared Olsen died in March 2015, less than a month after he was given the drug 6-mercaptopurine (6-MP) to treat his inflammatory bowel disease (IBD). The drug is known to cause adverse side effects in some people, including bone marrow toxicity. National medical standards require patients prescribed with 6-MP to undergo screening tests for the enzyme TPMT, which is needed to metabolise the drug. At the time of Mr Olsen’s admittance FSH did not have a policy regarding the safe prescription of the drug, although doctors did order a TPMT screen. However when the hospital’s electronic database generated the request for the test, it did so under the name of an intern on Mr Olsen’s treatment team. The test revealed Mr Olsen had severely low levels of TPMT, but when the results were released electronically none of the treating clinicians became aware of that fact. In her findings WA Coroner Ros Fogliani said if doctors had been aware of Mr Olsen’s TPMT levels any time soon after he was prescribed 6-MP, his bone marrow impairment would likely have been reversible. She said Mr Olsen’s death was a result of systemic failures within FSH, but did not make any adverse comments against the clinicians involved. In her findings Ms Fogliani recommended FSH install robust systems for tracking test results of discharged patients, and ensuring those results were provided to consultants in charge of the patient’s treatment. She also recommended such a system highlight urgent or abnormal test results. Ms Fogilani also recommended the Department of Health consider whether similar measures should be adopted across the public health system.
